Advanced Medicines
for Localised Delivery

We are developing advanced medicines using our novel technologies for the localised delivery of biologics, cell and gene therapies

Our advanced medicines, including cell and gene therapies, will heal tissues and organs damaged by age, disease or traumas

Product Pipeline

Our lead program is a next generation spinal fusion product, designed to reduce the total dose of BMP2 delivered during spinal fusions and enable minimally invasive surgery. Preclinical development will commence shortly to enable a first in man clinical study in 2021.

We are also evaluating additional pipeline opportunities utilising local tissue delivery of active agents including peptides, DNA, RNA and or cells eg T cells or MSCs.

Enabling Technologies

Our proprietary technologies are designed to overcome limitations with current biologic, cell and gene therapies 

TAOS is an injectable, biodegradable, 3-D tissue matrix, designed as a local delivery system for small molecule, biologic, gene and cell therapies. The high macroporosity of TAOS allows endogenous cells and blood vessels to penetrate the matrix, or for exogenous cells such as MSCs and T cells to be delivered to patients.

IntraStem is a novel peptide based intracellular delivery (transfection) technology that overcomes key limitations of viral and non-viral delivery systems at present, including for gene therapy.

Our two technologies can be combined to deliver advanced therapies locally, either to achieve high concentrations at the intended site of action and or to reduce systemic availability, to improve safety and or efficacy


Working with leaders in the regenerative medicine field

Locate has a pipeline agreement with the University of Nottingham which provides exclusive access to new technological breakthroughs through Locate’s scientific founder, Professor Kevin Shakesheff.

Partnering opportunities

Our technologies were invented by world-leading regenerative medicine scientists in the UK and have been developed by Locate over several years. 

Our TAOS® technology has been well validated through its use in  several of our pipeline programs and we have established its manufacture in house. TAOS can be used in a wide range of tissue types and therapy areas, supported by promising in vivo data.

IntraStem™ has a broad range of potential applications, including gene therapy, and offers major advantages over current transfection technologies. 

Locate is currently evaluating a number of new product opportunities for in-house development and for potential third party collaborations.